Founded in 2016, sRNAlytics has developed a computing platform capable of classifying patient samples with binary accuracy. Our products address an immediate need to incorporate biomarkers into drug discovery and development pipelines to satisfy FDA requirements, de-risk programs, and unlock billions of dollars through cost-savings and accelerated revenue realization.

 

World Class Team

We specialize in the discovery of classification biomarkers through next generation sequencing and data science.

David W. Salzman, PhD
Founder and CEO

Neal Foster, MBA
CBO

Nathan Ray
CTO

Alan P. Salzman, PhD
COO

 
 
sRNAlyticsHeadShots_Sean2.png
 
 

Sean Melville, MSc
Director of Business Development

 
 

Scientific Advisory Board

Frank J. Slack, PhD
Harvard Medical School

Richard H. Myers, PhD
BU Medical School

Joanne B. Weidhaas, MD, PhD
UCLA Medical School

Melanie L. Leitner, PhD
Accelerating Neuro

 
 
 
 

Blair R. Leavitt, MDCM, FRCP
University of British Columbia

 
 

Legal Advisors

 

Peter B. Finn, Esq.
Rubin and Rudman

 

Mark L. Hayman, PhD, JD
Morgan Lewis

 

There is a pervasive need to create new medicines for the treatment of diseases, which drives scientific breakthroughs and advances technology.
Combining new types of data, algorithms and computing platforms empowers sRNAlytics to create, and invent.
Join us in our mission to solve meaningful problems and make the world a better place.